AKT1 and glioblastoma: In combination with TMZ, another blood-brain barrier crossing Hsp90 inhibitor, onalespib showed a decrease in angiogenesis, migration, proliferation, and viability of patient-derived glioma-initiating cells and GBM cell lines by depleting several survival-promoting client proteins such as AKT, EGFRvIII, and EGFR, extended survival in several in vivo models [83].